Eur Rev Med Pharmacol Sci 2019; 23 (4): 1384-1385
DOI: 10.26355/eurrev_201902_17093

Comment on: Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma

B. Santella, D. Pignataro, M.A. Lavano, M. Rinaldi, F. Galdiero

Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy. bi.santella@gmail.com

Free PDF Download

To cite this article

B. Santella, D. Pignataro, M.A. Lavano, M. Rinaldi, F. Galdiero
Comment on: Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 4
Pages: 1384-1385
DOI: 10.26355/eurrev_201902_17093

Keywords Related articles:

  1. Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma
  2. Study on the distribution of CD8+ memory T cell subsets and IFN-γ level during the spontaneous clearance of hepatitis B virus in patients with chronic hepatitis B virus infection
  3. A personalized approach identifies disturbed pathways and key genes in hepatitis C virus-cirrhosis with hepatocellular carcinoma
  4. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis
  5. Platelet-to-lymphocyte ratio acts as an independent risk factor for patients with hepatitis B virus-related hepatocellular carcinoma who received transarterial chemoembolization